Nationwide Fund Advisors increased its stake in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) by 18.6% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 51,487 shares of the biotechnology company’s stock after buying an additional 8,069 shares during the period. Nationwide Fund Advisors’ holdings in Corcept Therapeutics were worth $608,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. Bank of Montreal Can boosted its holdings in shares of Corcept Therapeutics by 111.2% during the 2nd quarter. Bank of Montreal Can now owns 34,931 shares of the biotechnology company’s stock worth $413,000 after buying an additional 18,389 shares during the period. Birchview Capital LP boosted its holdings in shares of Corcept Therapeutics by 58.3% during the 2nd quarter. Birchview Capital LP now owns 95,000 shares of the biotechnology company’s stock worth $1,121,000 after buying an additional 35,000 shares during the period. Rhumbline Advisers boosted its holdings in shares of Corcept Therapeutics by 21.5% during the 2nd quarter. Rhumbline Advisers now owns 87,672 shares of the biotechnology company’s stock worth $1,035,000 after buying an additional 15,494 shares during the period. Prudential Financial Inc. boosted its holdings in shares of Corcept Therapeutics by 3,409.5% during the 2nd quarter. Prudential Financial Inc. now owns 633,223 shares of the biotechnology company’s stock worth $7,472,000 after buying an additional 615,180 shares during the period. Finally, Timpani Capital Management LLC bought a new stake in shares of Corcept Therapeutics during the 2nd quarter worth about $1,484,000. 62.22% of the stock is owned by institutional investors and hedge funds.

Corcept Therapeutics (NASDAQ:CORT) last issued its earnings results on Tuesday, August 1st. The biotechnology company reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of $0.08 by $0.02. The firm had revenue of $35.56 million during the quarter, compared to analyst estimates of $31.37 million. Corcept Therapeutics had a net margin of 22.28% and a return on equity of 51.45%. The company’s quarterly revenue was up 80.3% on a year-over-year basis. During the same quarter last year, the business earned $0.01 earnings per share.

Several analysts recently commented on CORT shares. Piper Jaffray Companies lifted their target price on shares of Corcept Therapeutics from $18.00 to $24.00 and gave the stock a “buy” rating in a report on Friday, September 8th. Stifel Nicolaus started coverage on shares of Corcept Therapeutics in a report on Thursday, August 31st. They set a “buy” rating and a $20.00 target price for the company. BidaskClub downgraded shares of Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, August 4th. Ladenburg Thalmann Financial Services set a $20.00 target price on shares of Corcept Therapeutics and gave the stock a “buy” rating in a report on Tuesday, July 18th. Finally, Zacks Investment Research downgraded shares of Corcept Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, October 10th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $17.17.

WARNING: This piece of content was originally posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://theolympiareport.com/2017/11/02/corcept-therapeutics-incorporated-cort-shares-bought-by-nationwide-fund-advisors.html.

Corcept Therapeutics Profile

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR).

Want to see what other hedge funds are holding CORT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Corcept Therapeutics Incorporated (NASDAQ:CORT).

Institutional Ownership by Quarter for Corcept Therapeutics (NASDAQ:CORT)

Receive News & Ratings for Corcept Therapeutics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.